


## IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A pharmaceutical composition ~~for improving cerebral function which comprises~~ comprising the following ingredients (A) and (B):

Ingredient (A): An alkyl ether derivative represented by the following formula:



wherein R<sup>1</sup> represents a substituted or unsubstituted heterocyclic group; R<sup>2</sup> represents a hydrogen atom or a hydroxyl group; R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, each represents a substituted or unsubstituted alkyl group, or R<sup>3</sup> and R<sup>4</sup>, taken conjointly with the nitrogen atom to which R<sup>3</sup> and R<sup>4</sup> are linked, form a substituted or unsubstituted cyclic amino group; m represents an integer of 1 to 5; and n represents an integer of 1 to 6; or a salt thereof,

Ingredient (B): A compound having an acetylcholine esterase inhibitory activity or a salt thereof, which is different from ingredient (A).

Claim 2 (Currently Amended): A pharmaceutical composition ~~for improving cerebral function~~ according to Claim 1, wherein in the formula of ingredient (A), R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, m and n meet any one of the following conditions (1) to (3):

(1) An alkyl ether derivative wherein R<sup>1</sup> is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group and a phenyl group; R<sup>2</sup> is a hydroxyl group; R<sup>3</sup> is an alkyl group; R<sup>4</sup> is an alkyl group which may be substituted with an alkoxy-substituted phenyl group, or R<sup>3</sup> and R<sup>4</sup>, taken conjointly with the nitrogen atom to which R<sup>3</sup> and R<sup>4</sup> are linked, form a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring; m is 1; and n is 2; or a salt thereof,


(2) An alkyl ether derivative wherein  $R^1$  is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group which may be substituted with a hydroxyl group, an alkoxy group, a carboxyl group, an aminocarbonyl group, a hydroxyl group, an alkylthio group, a phenyl group and a pyridyl group;  $R^2$  is a hydrogen atom;  $R^3$  is an alkyl group which may be substituted with a group selected from a phenyl group which may be substituted with a halogen atom, an alkoxy group or a nitro group, an optionally protected hydroxyl group, an alkylamino group and an alkynyl group;  $R^4$  is an alkyl group which may be substituted with a phenyl group; m is 1; and n is 2 to 3; or a salt thereof,

(3) An alkyl ether derivative wherein  $R^1$  is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group and a phenyl group;  $R^2$  is a hydrogen atom;  $R^3$  or  $R^4$  is an alkyl group which may be substituted with a group selected from a hydroxyl group, an optionally protected amino group and an alkylamino group, or  $R^3$  and  $R^4$ , taken conjointly with the nitrogen atom to which  $R^3$  and  $R^4$  are linked, form an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring; m is 1; and n is 2 to 3; or a salt thereof.

Claim 3 (Currently Amended): A pharmaceutical composition for improving cerebral function according to Claim 1 ~~or 2~~, wherein ingredient (B) is at least one compound selected from Tacrine, Donepezil, Rivastigmine, Galanthamine, Huperdine, Ipidacrine, Zanapezil, Phenserine, Quilostigmine, Ganstigmine, Ensaculin and T-82.

Claim 4 (Currently Amended): A method of preparing a medicament comprising combining the following ~~using the following~~ ingredients (A) and (B) ~~in combination in order to improve cerebral function,~~

Ingredient (A): An alkyl ether derivative represented by the following formula:



wherein  $\text{R}^1$  represents a substituted or unsubstituted heterocyclic group;  $\text{R}^2$  represents a hydrogen atom or a hydroxyl group;  $\text{R}^3$  and  $\text{R}^4$ , which may be the same or different, each represents a substituted or unsubstituted alkyl group, or  $\text{R}^3$  and  $\text{R}^4$ , taken conjointly with the nitrogen atom to which  $\text{R}^3$  and  $\text{R}^4$  are linked, form a substituted or unsubstituted cyclic amino group;  $m$  represents an integer of 1 to 5; and  $n$  represents an integer of 1 to 6; or a salt thereof,

Ingredient (B): A compound having an acetylcholine esterase inhibitory activity or a salt thereof, which is different from ingredient (A).

Claim 5 (Original): A method according to Claim 4, wherein in the formula of ingredient (A),  $\text{R}^1$ ,  $\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $m$  and  $n$  meet any one of the following conditions (1) to (3):

(1) An alkyl ether derivative wherein  $\text{R}^1$  is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group and a phenyl group;  $\text{R}^2$  is a hydroxyl group;  $\text{R}^3$  is an alkyl group;  $\text{R}^4$  is an alkyl group which may be substituted with an alkoxy-substituted phenyl group, or  $\text{R}^3$  and  $\text{R}^4$ , taken conjointly with the nitrogen atom to which  $\text{R}^3$  and  $\text{R}^4$  are linked, form a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring;  $m$  is 1; and  $n$  is 2; or a salt thereof,

(2) An alkyl ether derivative wherein  $\text{R}^1$  is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group which may be substituted with a hydroxyl group, an alkoxy group, a carboxyl group, an aminocarbonyl group, a hydroxyl group, an alkylthio group, a phenyl group and a pyridyl group;  $\text{R}^2$  is a hydrogen atom;  $\text{R}^3$  is an alkyl group which may be substituted with a group

selected from a phenyl group which may be substituted with a halogen atom, an alkoxy group or a nitro group, an optionally protected hydroxyl group, an alkylamino group and an alkynyl group; R<sup>4</sup> is an alkyl group which may be substituted with a phenyl group; m is 1; and n is 2 to 3; or a salt thereof,

(3) An alkyl ether derivative wherein R<sup>1</sup> is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group and a phenyl group; R<sup>2</sup> is a hydrogen atom; R<sup>3</sup> or R<sup>4</sup> is an alkyl group which may be substituted with a group selected from a hydroxyl group, an optionally protected amino group and an alkylamino group, or R<sup>3</sup> and R<sup>4</sup>, taken conjointly with the nitrogen atom to which R<sup>3</sup> and R<sup>4</sup> are linked, form an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring; m is 1; and n is 2 to 3; or a salt thereof.

Claim 6 (Currently Amended): A method according to Claim 4 ~~or 5~~, wherein ingredient (B) is at least one compound selected from Tacrine, Donepezil, Rivastigmine, Galanthamine, Huperzine, Ipidacrine, Zanapezil, Phenserine, Quilostigmine, Ganstigmine, Ensaculin and T-82.

Claim 7 (New): A pharmaceutical composition as claimed in claim 1 wherein the pharmaceutical composition is administered to a patient to improve cerebral function.

Claim 8 (New): A method as claimed in claim 4 further comprising administering the medicament to a patient in order to improve cerebral function.